Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection (vol 14, pg 4819, 2021)

被引：0
|
作者：
LeVee, A.
Lin, C. Y.
Posadas, E.
机构：
来源：
ONCOTARGETS AND THERAPY | 2021年 / 14卷
关键词：
D O I：
10.2147/OTT.S343977
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：5167 / 5167
页数：1
相关论文
共 50 条
  • [31] Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
    Francini, Edoardo
    Agarwal, Neeraj
    Castro, Elena
    Cheng, Heather H.
    Chi, Kim N.
    Clarke, Noel
    Mateo, Joaquin
    Rathkopf, Dana
    Saad, Fred
    Tombal, Bertrand
    EUROPEAN UROLOGY, 2025, 87 (01) : 29 - 46
  • [32] Neuroendocrine differentiation markers guide treatment sequence selection in metastatic castration-resistant prostate cancer
    Fan, Liancheng
    Yang, Yan
    Chi, Chenfei
    Ma, Xiaowei
    Wang, Rui
    Gong, Yiming
    Zheng, Hongying
    Pan, Jiahua
    Zhu, Yinjie
    Dong, Baijun
    Xue, Wei
    PROSTATE, 2019, 79 (06): : 567 - 573
  • [33] Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
    A. Rodriguez-Vida
    M. D. Torregrosa
    Á. Pinto
    M. Á. Climent
    D. Olmos
    J. Carles
    Clinical and Translational Oncology, 2018, 20 : 679 - 686
  • [34] Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223
    Rodriguez-Vida, A.
    Torregrosa, M. D.
    Pinto, A.
    Climent, M. A.
    Olmos, D.
    Carles, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (06): : 679 - 686
  • [35] COST-EFFECTIVENESS OF OLAPARIB COMPARED TO RUCAPARIB FOR THE TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN UNITED STATES
    Ghule, P.
    Kohli, M.
    Malone, D. C.
    Nelson, R. E.
    VALUE IN HEALTH, 2022, 25 (07) : S428 - S429
  • [36] Mutation Profile of Metastatic Castration-Resistant Prostate Cancer Patients Prior to Olaparib Treatment - EMA vs. FDA
    Dragos, Vita Setrajcic
    Stegel, Vida
    Klancar, Gasper
    Skerl, Petra
    Klasinc, Anja Zagozen
    Novakovic, Srdjan
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2023, 31 : 548 - 549
  • [37] Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
    Luo, Jia
    Graff, Julie N.
    RESEARCH AND REPORTS IN UROLOGY, 2016, 8 : 217 - 224
  • [38] Impact of abiraterone on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
    El-Amm, Joelle
    Nassabein, Rami
    Aragon-Ching, Jeanny B.
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 299 - 306
  • [39] Finding the optimal treatment sequence in metastatic castration-resistant prostate cancer-a narrative review
    Dror, Corinne Maurice
    Chi, Kim N.
    Khalaf, Daniel J.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) : 3931 - 3945
  • [40] Abiraterone for Treatment of Metastatic Castration-resistant Prostate Cancer: a Systematic Review and Meta-analysis
    Zhou, Zhi-Rui
    Liu, Shi-Xin
    Zhang, Tian-Song
    Xia, Jun
    Li, Bo
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2014, 15 (03) : 1313 - 1320
12345